Analyst Price Targets — TLPH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 13, 2026 11:03 am | Brandon Folkes | H.C. Wainwright | $3.00 | $1.40 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Talphera (TLPH) |
Latest News for TLPH
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion Cash and investments of…
SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TLPH.
U.S. House Trading
No House trades found for TLPH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.